Novo Nordisk eyes Denmark, UK, and Germany for Wegovy pill launch, targeting global weight loss market beyond US dominance.
Novo Nordisk raises 2026 outlook as Wegovy captures 65% of new US prescriptions, while Pandora faces tariff and silver price pressures.